Cargando…

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma

There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL). Bendamustine hydrochloride (bendamustine) has recently been approved for treatment of these patients. Bendamustine is a uniquely structured alkylating agent that lacks cross-res...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldoss, Ibrahim T, Blumel, Susan M, Bierman, Philip J
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004665/
https://www.ncbi.nlm.nih.gov/pubmed/21188134
_version_ 1782194021089673216
author Aldoss, Ibrahim T
Blumel, Susan M
Bierman, Philip J
author_facet Aldoss, Ibrahim T
Blumel, Susan M
Bierman, Philip J
author_sort Aldoss, Ibrahim T
collection PubMed
description There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL). Bendamustine hydrochloride (bendamustine) has recently been approved for treatment of these patients. Bendamustine is a uniquely structured alkylating agent that lacks cross-resistance with other alkylators. This agent has a high degree of activity against a variety of tumor cell lines. Clinically, bendamustine has demonstrated activity against indolent NHL, chronic lymphocytic lymphoma, multiple myeloma and mantle cell lymphoma. Moreover, studies have validated its activity in patients with indolent NHL who are resistant to purine analogs and rituximab. The cytotoxic activity of bendamustine has been shown to be synergistic with rituximab in hematological malignancies. The incidence of alopecia is significantly less than with other alkylating agents. Myelosuppression is the major toxicity associated with bendamustine.
format Text
id pubmed-3004665
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30046652010-12-23 The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma Aldoss, Ibrahim T Blumel, Susan M Bierman, Philip J Cancer Manag Res Review There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL). Bendamustine hydrochloride (bendamustine) has recently been approved for treatment of these patients. Bendamustine is a uniquely structured alkylating agent that lacks cross-resistance with other alkylators. This agent has a high degree of activity against a variety of tumor cell lines. Clinically, bendamustine has demonstrated activity against indolent NHL, chronic lymphocytic lymphoma, multiple myeloma and mantle cell lymphoma. Moreover, studies have validated its activity in patients with indolent NHL who are resistant to purine analogs and rituximab. The cytotoxic activity of bendamustine has been shown to be synergistic with rituximab in hematological malignancies. The incidence of alopecia is significantly less than with other alkylating agents. Myelosuppression is the major toxicity associated with bendamustine. Dove Medical Press 2009-11-12 /pmc/articles/PMC3004665/ /pubmed/21188134 Text en © 2009 Aldoss et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Aldoss, Ibrahim T
Blumel, Susan M
Bierman, Philip J
The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
title The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
title_full The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
title_fullStr The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
title_full_unstemmed The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
title_short The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
title_sort role of bendamustine in the treatment of indolent non-hodgkin lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004665/
https://www.ncbi.nlm.nih.gov/pubmed/21188134
work_keys_str_mv AT aldossibrahimt theroleofbendamustineinthetreatmentofindolentnonhodgkinlymphoma
AT blumelsusanm theroleofbendamustineinthetreatmentofindolentnonhodgkinlymphoma
AT biermanphilipj theroleofbendamustineinthetreatmentofindolentnonhodgkinlymphoma
AT aldossibrahimt roleofbendamustineinthetreatmentofindolentnonhodgkinlymphoma
AT blumelsusanm roleofbendamustineinthetreatmentofindolentnonhodgkinlymphoma
AT biermanphilipj roleofbendamustineinthetreatmentofindolentnonhodgkinlymphoma